Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report

Purpose Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult. Case description Case description We present a case of a 26 year old patient, a soldier with COVID-19 and no comorbidities, who developed marked sinus bradycardia during remdesivir therapy. The bradycardia resolved few days after the end of antiviral treatment. Conclusion Our case emphasizes the key importance of the correct monitoring of patients receiving remdesivir, even those who do not have pre-existing heart conditions.